肝细胞肝癌与肝移植

摘要/Abstract

摘要： 肝细胞癌(HCC)是最常见的肝脏原发性恶性肿瘤。肝移植治疗肝细胞癌(HCC)对合并肝硬化患者是根治性的治疗，包括肿瘤和相关的癌前状态，尤其是肝癌的发展源于慢性肝病的基础上的患者。器官移植供体的短缺已导致等待时间延长，由于肿瘤的进展，从排队序列中被剔除风险增加。新辅助治疗，肝动脉化疗栓塞(TACE)，射频消融(RFA)、经皮无水乙醇注射(PEI)作为过渡治疗控制肿瘤的生长。尽管选择标准的扩展是必要的，但它应该建立在良好设计的前瞻性研究的评估之上。本研究展现了德国包括单中心(汉诺威医学院)在肝细胞癌肝移植方面的经验，合理使用肝移植更有利于人类。

关键词: 肝细胞癌, 肝移植, 活体供体肝移植, 治疗

Abstract: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver.Liver transplantation for hepatocellular carcinoma (HCC) in patients with cirrhosis is a radical treatment of the tumor and associated precancerous state,especially for HCC developing within an established background of chronic liver disease.Shortage of organ donors has resulted in overall increase of waiting list time with increased risk of dropout due to tumor progression.Neoadjuvant therapies,transarterial chemoembolization (TACE),radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) have emerged as bridging therapy to control tumor growth.Although expansion of selection criteria is necessary,it should be assessed in the setting of prospective well-designed studies.This research presents German experience including single-center (medical school of Hannover) of undergoing transplantation for HCC.Rational use of liver transplantation is more beneficial for humanbeing.

Key words: Hepatocellular carcinoma, Liver transplantation, Living donor liver transplantation, Treatment

中图分类号:

赵泽明，BeckerThomas，FANYue-zu，RingeBastian，KlempnauerJürgen. 肝细胞肝癌与肝移植[J]. 外科研究与新技术, 2013, 2(4): 219-224.

ZHAO Ze-ming, Becker Thomas, FAN Yue-zu, Ringe Bastian, Klempnauer Jürgen. Hepatocellular carcinoma (HCC) & liver transplantation (LT)[J]. Surgical Research and New Technique, 2013, 2(4): 219-224.

参考文献

[1] Feitelson MA.Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma[J].Cancer Lett,2006,239(1):10-20.
[2] Lotze M FJ,Carr B.Hepatobiliary Neoplasms In: Devita VT,Rosenberg SA,eds.Cancer: principles and practice of oncology[M].Philadelphia:Lippincott,1993.
[3] Parkin DM,Bray F,Ferlay J,Pisani P.Estimating the world cancer burden: Globocan 2000[J].Int J Cancer,2001,94(2):153-156.
[4] El-Serag HB,Mason AC.Rising incidence of hepatocellular carcinoma in the United States[J].N Engl J Med,1999,340(10):745-750.
[5] Bosch FX,Ribes J,Diaz M,Cleries R.Primary liver cancer: worldwide incidence and trends[J].Gastroenterology,2004,127(5 Suppl 1):S5-S16.
[6] Sangiovanni A,Del Ninno E,Fasani P,et al.Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance[J].Gastroenterology,2004,126(4):1005-1014.
[7] Bosch FX,Ribes J,Borras J.Epidemiology of primary liver cancer[J].Semin Liver Dis,1999,19(3):271-285.
[8] The World health report (2003) shaping the future[R].World Health Organization,2003.
[9] Zhou XD,Tang ZY,Yu YQ,et al.Long-term survivors after resection for primary liver cancer.Clinical analysis of 19 patients surviving more than ten years[J].Cancer,1989,63(11):2201-2206.
[10] Belghiti J,Panis Y,Farges O,et al.Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis[J].Ann Surg,1991,214(2):114-117.
[11] Starzl TE MT,Vonkaulla KN,Hemann G,Brittain,RS WW.Homotransplantation of the liver in humans[J].Surg Gynecol Obstet,1963,117(12):659-676.
[12] Iwatsuki S,Gordon RD,Shaw BW,Jr.,Starzl TE.Role of liver transplantation in cancer therapy[J].Ann Surg,1985,202(4):401-407.
[13] O’Grady JG,Polson RJ,Rolles K,et al.Liver transplantation for malignant disease.Results in 93 consecutive patients[J].Ann Surg,1988,207(4):373-379.
[14] Ringe B,Wittekind C,Bechstein WO,et al.The role of liver transplantation in hepatobiliary malignancy.A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence[J].Ann Surg,1989,209(1):88-98.
[15] Ismail T,Angrisani L,Gunson BK,et al.Primary hepatic malignancy: the role of liver transplantation[J].Br J Surg,1990,77(9):983-987.
[16] Olthoff KM,Millis JM,Rosove MH,et al.Is liver transplantation justified for the treatment of hepatic malignancies? [J].Arch Surg,1990,125(10):1261-1266;discussion 1266-1268.
[17] Haug CE,Jenkins RL,Rohrer RJ,et al.Liver transplantation for primary hepatic cancer[J].Transplantation,1992,53(2):376-382.
[18] Moreno Gonzalez E,Gomez R,Garcia I,et al.Liver transplantation in malignant primary hepatic neoplasms[J].Am J Surg,1992,163(4):395-400.
[19] Penn I.Hepatic transplantation for primary and metastatic cancers of the liver[J].Surgery,1991,110(4):726-734;discussion 734-735.
[20] Freeman RB,Jr.Transplantation for hepatocellular carcinoma: The Milan criteria and beyond[J].Liver Transpl,2006,12(11 Suppl 2):S8-S13.
[21] Ringe B,Pichlmayr R,Wittekind C,Tusch G.Surgical treatment of hepatocellular carcinoma:experience with liver resection and transplantation in 198 patients[J].World J Surg,1991,15(2):270-285.
[22] Iwatsuki S,Starzl TE,Sheahan DG,et al.Hepatic resection versus transplantation for hepatocellular carcinoma[J].Ann Surg,1991,214(3):221-228;discussion 228-229.
[23] Yokoyama I,Todo S,Iwatsuki S,Starzl TE.Liver transplantation in the treatment of primary liver cancer[J].Hepatogastroenterology,1990,37(2):188-193.
[24] Llovet JM,Fuster J,Bruix J.Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma:resection versus transplantation[J].Hepatology,1999,30(6):1434-1440.
[25] Mazzaferro V,Regalia E,Doci R,et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].N Engl J Med,1996,334(11):693-699.
[26] Bismuth H,Majno PE,Adam R.Liver transplantation for hepatocellular carcinoma[J].Semin Liver Dis,1999,19(3):311-322.
[27] Jonas S,Bechstein WO,Steinmuller T,et al.Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis[J].Hepatology,2001,33(5):1080-1086.
[28] Bismuth H,Chiche L,Adam R,et al.Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients[J].Ann Surg,1993,218(2):145-151.
[29] Yao FY,Ferrell L,Bass NM,et al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J].Hepatology,2001,33(6):1394-1403.
[30] Chan SC.Liver transplantation for hepatocellular carcinoma[J].Liver Cancer,2013,2(3-4):338-344.
[31] Livraghi T.Radiofrequency ablation,PEIT,and TACE for hepatocellular carcinoma[J].J Hepatobiliary Pancreat Surg,2003,10(1):67-76.
[32] Jansen MC,van Hillegersberg R,Chamuleau RA,et al.Outcome of regional and local ablative therapies for hepatocellular carcinoma:a collective review[J].Eur J Surg Oncol,2005,31(4):331-347.
[33] Moreno Planas JM,Lopez Monclus J,Gomez Cruz A,et al.Efficacy of hepatocellular carcinoma locoregional therapies on patients waiting for liver transplantation[J].Transplant Proc,2005,37(3):1484-1485.
[34] Rust C,Gores GJ.Locoregional management of hepatocellular carcinoma.Surgical and ablation therapies[J].Clin Liver Dis,2001,5(1):161-173.
[35] Ahrar K,Gupta S.Hepatic artery embolization for hepatocellular carcinoma: technique,patient selection,and outcomes[J].Surg Oncol Clin N Am,2003,12(1):105-126.
[36] Zarrinpar A, Busuttil RW.Liver transolantation:past,present and future[J].Nat Rev Gastroenterol Hepatol,2013,10(7):434-440.
[37] Pichlmayr R,Ringe B,Gubernatis G,et al.Transplantation of a donor liver to 2 recipients (splitting transplantation)—a new method in the further development of segmental liver transplantation[J].Langenbecks Arch Chir,1988,373(2):127-130.
[38] Sala M,Varela M,Bruix J.Selection of candidates with HCC for transplantation in the MELD era[J].Liver Transpl,2004,10(10 Suppl 2):S4-S9.